Great Bay Bio Recognized as One of the Top 50 Innovative Biotechnology Companies in Guangdong-Hong Kong-Macao Greater Bay Area Award 2024
December 30, 2024 |
AEF |
Portfolio
Share :
*This content is only available in English.
The Guangdong-Hong Kong-Macao Greater Bay Area Biotech Innovation Summit and the 7th Top 50 Innovative Biotech Companies in Greater Bay Area selection event were recently held in Guangzhou. Great Bay Bio (GBB) was successfully listed among the Top 50 Innovative Biotech Companies of the 7th Annual Guangdong-Hong Kong-Macao Greater Bay Area Biotech Innovation Awards 2024 and also won two prestigious honors, “Most Valuable Investment Enterprise 2024” and “The Pioneer Enterprise”.
Most Valuable Investment Enterprise 2024
The Pioneer Enterprise
The event was organized by SINO-INNO RESEARCH, hosted by MEDV, and co-organized by the China Merchants Bank Guangzhou Branch. The event aims to promote further the cluster development of the Greater Bay Area’s biotech industry and create a vibrant and highly competitive life sciences ecosystem. GBB drives drug development through cutting-edge technologies such as AI, big data mining, and automation, empowering the drug discovery and CMC development process. This has brought revolutionary changes to biopharmaceutical development, accelerating and improving product development for numerous domestic and international clients, showcasing its strong growth potential.
Dr. Miao Hongjiang (second from right), AI CTO of GBB, attended the Awards Ceremony
Following the successful Series A and Pre-B rounds financing, GBB has once again attracted investor interest and completed the first close of Series B financing. This achievement has earned it well-deserved recognition as the Most Valuable Investment Enterprise 2024.
Most Valuable Investment Enterprise 2024
The Pioneer Enterprise
Dr. Miao Hongjiang (second from right), AI CTO of GBB, attended the Awards Ceremony
Most Valuable Investment Enterprise 2024
The Pioneer Enterprise
